| Reference-based pricing in British Columbia: implications for cardiologists--an analysis. | |
| | |
MedLine Citation:
|
PMID: 9039064 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Under the reference-based pricing (RBP) policy, British Columbia will fund drug therapies based on the cost of the 'gold standard' therapy that meets the needs of the majority of patients with a specific condition. Hence, Pharmacare will pay for the lowest cost drug within a cluster of related but different drugs, regardless of the indication. When evaluating the impact of drugs on health care expenditure, one must consider that their costs are more than offset by the clinical and economic benefits they provide. Pharmaceutical expenditure accounts for a small proportion of health care expenditure and should be viewed as an essential and interactive component in the global health care budget rather than as an independent constituent. In that respect, insight should be gained from many countries in which RBP has been implemented A wealth of data converge to the same conclusion: price controls and restricted access to drugs do not reduce prescription drug expenditures but actually increase health care costs. Furthermore, cost containment being the main issue behind RBP in British Columbia, the contentious issue of therapeutic substitution has not been taken fully into consideration, nor has its impact on the quality of care of the patient. The case of diltiazem once-a-day versus diltiazem tablets for hypertensive and angina patients illustrates the important considerations that must be taken into account in writing the overall financial equation that drives the implementation of the RBP policy. If pharmacotherapy is to be an appropriate treatment to attain optimal cost effective health care, its benefit can only be optimized with a strategy that entails the right therapy, for the right patient, in the right dosage form and at the right time. Accordingly, RBP in British Columbia should be analyzed in light of patient welfare and appropriate use of collective resources. |
| | |
Authors:
|
A P Boulet; G Tessier |
Related Documents
:
|
7264294 - Identification of supplier induced demand in the health care sector. 16438784 - User charges in public health facilities in tanzania: effect on revenues, quality of se... 20864204 - Fiscal decentralization in the italian nhs: what happens to interregional redistribution? 9636934 - Differences between descriptive and multivariate estimates of the impact of chevron cor... 14654504 - Multi-agency, multi-professional work: experiences from a drug prevention project. 22512774 - What is driving people's dissatisfaction with their own health care in 17 latin america... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Canadian journal of cardiology Volume: 13 ISSN: 0828-282X ISO Abbreviation: Can J Cardiol Publication Date: 1997 Jan |
Date Detail:
|
Created Date: 1997-03-07 Completed Date: 1997-03-07 Revised Date: 2008-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 8510280 Medline TA: Can J Cardiol Country: CANADA |
Other Details:
|
Languages: eng Pagination: 46-51 Citation Subset: IM |
Affiliation:
|
Health Economics Department, Hoechst Marion Roussel Canada Research Inc, Laval, Quebec. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina Pectoris
/
drug therapy Antihypertensive Agents / administration & dosage, economics* British Columbia Cardiovascular Agents / administration & dosage, economics* Cost Control / methods Diltiazem / administration & dosage, economics Drug Administration Schedule Drug Costs / trends* Drugs, Generic / economics Humans Hypertension / drug therapy Patient Compliance Prescription Fees / trends* Quality of Health Care |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Cardiovascular Agents; 0/Drugs, Generic; 42399-41-7/Diltiazem |
| Comments/Corrections | |
Comment In:
|
Can J Cardiol. 1997 Jan;13(1):31-2
[PMID:
9039062
]
Can J Cardiol. 1997 Jul;13(7):640, 689 [PMID: 9251575 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vasopressin constricts outer medullary descending vasa recta isolated from rat kidneys.
Next Document: Sotalol-induced torsades de pointes in patients with renal failure.